This presentation is on the medications semaglutide and tirzepatide , prescribed under brand names such as Ozempic, Wegovy and Monjaro, and others, some of which are in development. These drugs are GLP-1 agonist medications most commonly used for the treatment of type 2 diabetes, but more recently it’s been in the spotlight as a medication for weight loss, causing controversy, misunderstanding, questions and significant shortages of the medication.

Dr. DeSarbo will briefly look at these medications from all perspectives including their use in diabetes, as a weight loss drug for the medical definition of obesity, and their potential impact and fallout with the eating disorder population.

Research in treatment collaboration, neural activation with social interactions and change, importance of neuroscience education to the patient, virtual reality treatment with eating disorders. Part two: interview with Robyn L. Goldberg, RDN, CEDRD-S and author The Eating Disorder Trap.  Robyn is a very experienced RDN with specialization in eating disorders and bogy image treatment. Her new book is a comprehensive guide for clinicians and loved ones covering the multiple aspects of anorexia nervosa, bulimia nervosa, binge eating disorder and related conditions. Robyn discusses how she found her way into the eating disorder field and the motivation for her book. 

Dr. Jeffrey DeSarbo and Lukas DeSarbo, LMSW discuss recent research of eating disorders and COVID-19 including their paper on Anorexia Nervosa and CVID-19.